Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial

Blood Lymphocyte-to-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

(2012) Zhi-Ming Li et al.   PLoS One

PTLD treatment: a step forward, a long way to go

(2011) Emili Montserrat   LANCET ONCOLOGY

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

(2011) Ralf Trappe et al.   LANCET ONCOLOGY

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma

(2011) R A Wilcox et al.   LEUKEMIA

Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio

(2010) Luis F. Porrata et al.   AMERICAN JOURNAL OF HEMATOLOGY

Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy

(2009) M.-K. Song et al.   ANNALS OF ONCOLOGY

Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab

(2008) Yasuhiro Oki et al.   EUROPEAN JOURNAL OF HAEMATOLOGY